Ankylosing spondylitis

Conference Coverage

FDA’s Woodcock: Give biosimilars a chance

BOSTON – Biosimilar drugs are not identical twins of original biologic agents, but there are very strong family ties, and the newcomer is expected...

MD IQ

Conference Coverage

Biosimilars face barriers to broader acceptance

BOSTON – For rheumatologists, the primary selling points of biosimilar agents are their presumed efficacy and safety, and their promised cost...

Pages